Abstract
Elderty and geriatrie patients represent a significant proportion of patients with rheumatic diseases. It is a specific popula- tion that is beyond the physiological changes accompanying aging also burdened by high concurrent polymorbidity and poly- pharmacy and higher risk of side effeets.
In generál, none of the current antirheumatic therapies is contraindicated solely because of age, but for each patient it is necessary to individually assess the benefit of the treatment and assess its risks in terms of side effeets and drug interactions before initiating treatment. In generál it is recommended that elderty patients shoutd be administered agents with lower toxicity and short or medium half-life, initiating treatment at lower doses than the generál population, and inereasing them gradually according to tolerance.
It is necessary to ensure good cooperation of the patient oř his / her family regarding the use and dosage of the drug, further advise the patient on possible side effeets and regularly evaluate the safety of the treatment according to the guidelines